240
Views
3
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Efficacy and Safety of Combination Antifungals as Empirical, Preemptive, and Targeted Therapies for Invasive Fungal Infections in Intensive-Care Units

, , , , , , , , , & show all
Pages 5331-5344 | Received 12 Jul 2022, Accepted 29 Aug 2022, Published online: 09 Sep 2022

References

  • Lilienfeld-Toal MV, Wagener J, Einsele H, et al. Invasive fungal infection. Dtsch Arztebl Int. 2019;116(16):271–278. doi:10.3238/arztebl.2019.0271
  • Delaloye J, Calandra T. Invasive candidiasis as a cause of sepsis in the critically ill patient. Virulence. 2014;5(1):161–169. doi:10.4161/viru.26187
  • Schmiedel Y, Zimmerli S. Common invasive fungal diseases: an overview of invasive candidiasis, aspergillosis, cryptococcosis, and Pneumocystis pneumonia. Swiss Med Wkly. 2016;146. doi:10.4414/smw.2016.14281
  • Ibrahim-Granet OG, Rekiki A, Savers A, et al. New insights into the pathogenesis of invasive pulmonary aspergillosis: real time imaging of hypoxia and inflammation. Mycoses. 2013;56:145–146. doi:10.1111/j.1439-0507.2012.02224.x
  • Cortes LJ, Russi NJ. Equinocandinas. Rev Chilena Infectol. 2011;28(6):529–536. Spanish.
  • Hargrove TY, Wawrzak Z, Lamb DC, et al. Structure-functional characterization of cytochrome P450 sterol 14alpha-demethylase (CYP51B) from aspergillus fumigatus and molecular basis for the development of antifungal drugs. J Biol Chem. 2015;290(39):23916–23934. doi:10.1074/jbc.M115.677310
  • Fukasawa M. リソーマルアムホテリシンB. Nihon Ishinkin Gakkai Zasshi. 2005;46(4):229–231. Japanese. doi:10.3314/jjmm.46.229
  • Perea S, Gonzalez G, Fothergill AW, et al. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of aspergillus spp. Antimicrob Agents Chemother. 2002;46(9):3039–3041. doi:10.1128/aac.46.9.3039-3041.2002
  • Kirkpatrick WR, Perea S, Coco BJ, et al. Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother. 2002;46(8):2564–2568. doi:10.1128/AAC.46.8.2564-2568.2002
  • Marr KA, Schlamm HT, Herbrecht R, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2015;162(2):81–89. doi:10.7326/M13-2508
  • Arikan S, Lozano-Chiu M, Paetznick V, et al. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002;46(1):245–247. doi:10.1128/AAC.46.1.245-247.2002
  • Clemons KV, Espiritu M, Parmar R, et al. Comparative efficacies of conventional amphotericin b, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother. 2005;49(12):4867–4875. doi:10.1128/AAC.49.12.4867-4875.2005
  • Maertens J, Glasmacher A, Herbrecht R, et al. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer. 2006;107(12):2888–2897. doi:10.1002/cncr.22348
  • Caillot D, Thiebaut A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer. 2007;110(12):2740–2746. doi:10.1002/cncr.23109
  • Pappas PG, Kauffman CA, Andes DR, et al. clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–50. doi:10.1093/cid/civ933
  • Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
  • Muilwijk EW, Schouten JA, Van Leeuwen HJ, et al. Pharmacokinetics of caspofungin in ICU patients. J Antimicrob Chemother. 2014;69(12):3294–3299. doi:10.1093/jac/dku313
  • Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–1151. doi:10.1016/S0140-6736(03)14472-8
  • De Pascale G, Tumbarello M. Fungal infections in the ICU: advances in treatment and diagnosis. Curr Opin Crit Care. 2015;21(5):421–429. doi:10.1097/MCC.0000000000000230
  • Martin-Pena A, Aguilar-Guisado M, Espigado I, et al. Antifungal combination therapy for invasive aspergillosis. Clin Infect Dis. 2014;59(10):1437–1445. doi:10.1093/cid/ciu581
  • Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563–1571. doi:10.1086/423381
  • Denning DW, Ribaud P, Milpied N, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34(5):563–571. doi:10.1086/324620
  • Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis. 1998;26(6):1383–1396. doi:10.1086/516353
  • Lee DG, Lee HJ, Yan JL, et al. Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis. Mycoses. 2019;62(10):969–978. doi:10.1111/myc.12972
  • Qiu KY, Liao XY, Fang JP, et al. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders. Transpl Infect Dis. 2019;21(3):e13066. doi:10.1111/tid.13066
  • Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98(2):292–299. doi:10.1002/cncr.11479
  • Haidar G, Singh N. How we approach combination antifungal therapy for invasive aspergillosis and mucormycosis in transplant recipients. Transplantation. 2018;102(11):1815–1823. doi:10.1097/TP.0000000000002353
  • Mihu CN, Kassis C, Ramos ER, et al. Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients? Cancer. 2010;116(22):5290–5296. doi:10.1002/cncr.25312
  • De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46(12):1813–1821. doi:10.1086/588660
  • Freemantle N, Tharmanathan P, Herbrecht R. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother. 2011;66(Suppl 1):i25–35. doi:10.1093/jac/dkq439
  • Jin H, Wang T, Falcione BA, et al. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis. J Antimicrob Chemother. 2016;71(7):1772–1785. doi:10.1093/jac/dkw045
  • Sideri G, Falagas ME, Grigoriou M, et al. Liposomal amphotericin B in critically ill paediatric patients. J Clin Pharm Ther. 2012;37(3):291–295. doi:10.1111/j.1365-2710.2011.01288.x
  • Silva S, Negri M, Henriques M, et al. Candida glabrata, Candida parapsilosis and Candida tropicalis: biology, epidemiology, pathogenicity and antifungal resistance. FEMS Microbiol Rev. 2012;36(2):288–305. doi:10.1111/j.1574-6976.2011.00278.x
  • Garbati MA, Alasmari FA, Al-Tannir MA, et al. The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review. Int J Infect Dis. 2012;16(2):e76–81. doi:10.1016/j.ijid.2011.10.004
  • Ostrosky-Zeichner L, Shoham S, Vazquez J, et al. MSG-01: a randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis. 2014;58(9):1219–1226. doi:10.1093/cid/ciu074
  • Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(Suppl 7):19–37. doi:10.1111/1469-0691.12039
  • Cui N, Wang H, Qiu H, et al. Impact of initial empirical antifungal agents on the outcome of critically ill patients with invasive candidiasis: analysis of the China-SCAN study. Int J Antimicrob Agents. 2017;50(1):74–80. doi:10.1016/j.ijantimicag.2017.02.019
  • Leon-Gil C, Ubeda-Iglesias A, Loza-Vazquez A, et al. Efficacy and safety of caspofungin in critically ill patients. ProCAS study. Rev Esp Quimioter. 2012;25(4):274–282.
  • Dupont H, Mahjoub Y, Chouaki T, et al. Antifungal prevention of systemic candidiasis in immunocompetent ICU adults: systematic review and meta-analysis of clinical trials. Crit Care Med. 2017;45(11):1937–1945. doi:10.1097/CCM.0000000000002698
  • Raad II, Zakhem AE, Helou GE, et al. Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies. Int J Antimicrob Agents. 2015;45(3):283–288. doi:10.1016/j.ijantimicag.2014.08.012
  • Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2014;28:80–94. doi:10.1016/j.ijid.2014.07.007
  • Thomas A, Korb V, Guillemain R, et al. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis. J Clin Pharm Ther. 2010;35(1):49–53. doi:10.1111/j.1365-2710.2009.01061.x
  • O’Shaughnessy EM, Meletiadis J, Stergiopoulou T, et al. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J Antimicrob Chemother. 2006;58(6):1168–1176. doi:10.1093/jac/dkl392
  • Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97(4):1025–1032. doi:10.1002/cncr.11115
  • Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004;39(6):797–802. doi:10.1086/423380